Aptevo Therapeutics Inc.
Moat Score — Aptevo Therapeutics Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Aptevo's ADAPTIR bispecific antibody engineering platform is a genuine proprietary technology protected by patents, though bispecific antibody engineering is no longer a novel or exclusive capability given how many well-funded competitors have mastered similar formats. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small, capital-constrained clinical-stage biotech, Aptevo has no manufacturing or development cost advantage versus large, well-funded bispecific antibody competitors like Amgen or Roche. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved commercial product, Aptevo currently has no pricing power, and even if a candidate reached approval it would compete against multiple established bispecific oncology therapies. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A bispecific antibody therapy platform exhibits no network effect between patients, physicians, or partners. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no commercial product on the market, there is no customer relationship or switching-cost dynamic currently in place. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The bispecific antibody oncology space is crowded with large, well-capitalized competitors, so efficient-scale dynamics provide no protection to a small platform company like Aptevo. |